---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290881025.md"
description: "Taysha Gene Therapies Announces Multiple Presentations Highlighting TSHA-102 Program In Clinical Evaluation For Rett Syndrome At 2026 IRSF Rett Syndrome Scientific Meeting"
datetime: "2026-06-25T20:02:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290881025.md)
  - [en](https://longbridge.com/en/news/290881025.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290881025.md)
generator: "portal-rs"
---

# 

Taysha Gene Therapies Announces Multiple Presentations Highlighting TSHA-102 Program In Clinical Evaluation For Rett Syndrome At 2026 IRSF Rett Syndrome Scientific Meeting

### Related Stocks

- [TSHA.US](https://longbridge.com/en/quote/TSHA.US.md)

## Related News & Research

- [Taysha Gene Therapies grants new hires 314,000 RSUs, 92,400 options at $5.7 strike](https://longbridge.com/en/news/298034947.md)
- [Taysha Gene Therapies highlights TSHA-102 Rett gene therapy path toward BLA submission in corporate presentation](https://longbridge.com/en/news/297550820.md)
- [These 3 Risky Stocks Could Be Sitting on 100% Upside](https://longbridge.com/en/news/298224661.md)
- [TSHA: TSHA-102 trials completed dosing; topline data and FDA feedback expected in 1H 2027](https://longbridge.com/en/news/295573802.md)
- [Taysha Gene Therapies Q2 net loss widens on higher R&D costs](https://longbridge.com/en/news/295573772.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**